Testagen
Lys-Glu-Asp-Gly · KEDG · Testis bioregulator
Think of it as a personal trainer for your reproductive cells.
Testagen is a small peptide that aims to give your reproductive system a little pep talk, encouraging cells in the prostate and testis to express their genes more effectively. Imagine it like a personal trainer that knows exactly how to motivate these cells, potentially improving their performance.
Research suggests that Testagen can influence the way genes are expressed in reproductive tissues, which might impact hormone signaling. It's been studied in cell cultures and animals for its ability to rejuvenate reproductive tissues, especially as they age. However, it's still early days, and this peptide isn't FDA-approved yet, so it's mostly in the research and curiosity phase rather than a mainstream solution.
Who it's for
- Men curious about boosting reproductive health as they age
- Biohackers interested in cutting-edge peptide research
- People exploring non-mainstream wellness solutions
Probably not for you if…
- Anyone looking for FDA-approved treatments
- Those unwilling to try unproven supplements
- Individuals expecting quick, guaranteed results
Editorial summary for research context · Not medical advice
Mechanism of Action
Testagen is a short synthetic tetrapeptide (Lys-Glu-Asp-Gly) from the Khavinson family of tissue-specific bioregulators. Research from the St. Petersburg Institute of Bioregulation and Gerontology proposes that short peptides of this class penetrate the cell membrane, localize to the nucleus, and bind promoter regions of DNA — modulating tissue-specific gene expression in prostate and testicular tissue. Not FDA-approved. Preclinical and limited human data.
Researched Benefits
Prostate and testicular gene expression
Khavinson-group studies report modulation of gene expression in prostate and testis cell cultures, with proposed effects on androgen-pathway signaling.
- [Khavinson 2014]
- [Anisimov & Khavinson 2010]
Age-related reproductive tissue research
Preclinical rodent work has examined restoration of reproductive tissue morphology in aged animals following tetrapeptide administration.
- [Khavinson et al. 2011]
Research Protocols
The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.
Intranasal research protocol
- Dosage
- 100 mcg
- Frequency
- once daily
- Timing
- morning
- Cycle
- 3 weeks
Khavinson-group protocols have typically used short 20-30 day cycles, often repeated 2-3 times per year.
Reported Side Effects
- Minimal adverse events reported in published Khavinson-group studies
- Local irritation with intranasal administration reported anecdotally
- Long-term human safety data limited
Contraindications
- Pregnancy and lactation (no safety data)
- Active malignancy of prostate or testicular tissue (theoretical concern)
- Individual hypersensitivity to peptide components
Stacking Partners
Peptides commonly paired with Testagen in published research and protocol write-ups.
Vendor Pricing
Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.
Top Videos
Curated from YouTube — refreshed weekly. Stacked doesn't host or endorse external content.
6:04Doctor Explains 20 Most Powerful Peptides
This Is Not Covered - Dr. Ashley Froese
472.6K views · 6:04 · 7 months ago
7:43Why I Stopped BPC-157 and TB-500 Peptides - April 26, 2024
Bill Maeda
366.9K views · 7:43 · 2 years ago
5:59TIER LIST PEPTIDE EDITION
Greg Doucette
351.9K views · 5:59 · 1 year ago
4:50Doctor Reviews TOP Peptides For Fat Loss, Energy, & Endurance
This Is Not Covered - Dr. Ashley Froese
162.2K views · 4:50 · 8 months ago
7:14Doctor Explains 10 Most Fascinating Peptides
This Is Not Covered - Dr. Ashley Froese
110.5K views · 7:14 · 7 months ago
Research Papers
Peptides and Aging: Bioregulation of Gene Expression and Longevity
Khavinson VKh · Neuroendocrinology Letters · 2014
Peptide bioregulators: the new class of geroprotectors
Anisimov VN, Khavinson VKh · Advances in Gerontology · 2010
